SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VK2735s obesity-trial resultsshowing substantial weight-loss retention with less-frequent dosing and continued weight loss with weekly treatmenthave driven a sharp rally. Many traders view the data as strengthening Vikings competitive position and fueling possible buyout or partnership interest, while others point to unconfirmed deal speculation, potential dilution, competition and volatile trading.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs claimed real-time quantum error-correction decoder running on a standard CPU is driving discussion, with bullish traders viewing it as progress toward fault-tolerant systems and skeptics arguing the demonstration is simulation-based and overhyped. The announcement has prompted excitement about quantum-sector momentum alongside caution about whether the technology will scale in hardware.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

Coreturas selection of BlackBerrys QNX-backed Alloy Kore platform for its commercial-vehicle software platform is drawing attention as a major design win and addition to QNXs royalty backlog. Bulls view it as validation of future growth, while skeptics question how quickly the backlog will translate into revenue; expectations for the quarterly report and guidance are also driving debate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer is the dominant focus, with traders also watching upcoming biomarker data and manufacturing validation. Optimism over the positive Phase 3 results and managements on-track guidance is tempered by concerns that the timeline is tight, amplified by reaction to CEO Paul Peter Taks preplanned share sale.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rebound toward the ten-cent level is driving attention, with traders pointing to chart breakouts and renewed crypto-market momentum while watching resistance. Bullish hopes for a sustained move are tempered by concerns that recent pops will fade, as well as uncertainty over the Clarity Act and broader crypto conditions.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcashs sharp rally to record highs is driving attention, with bullish traders pointing to renewed demand for privacy-focused crypto and the Grayscale Zcash ETFs announced share split. Many also attribute momentum to short covering, while others warn the rapid run may be overextended and vulnerable to a pullback.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions quantum error-correction work integrating its qLDPC library with NVIDIA CUDA-Q Logical is drawing attention, with bulls viewing the collaboration as progress toward fault-tolerant computing. Traders are also frustrated that the stock has not responded consistently to the technical news, pointing to volatility and broader market conditions as counterweights.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgeralds upgrade to Overweight, citing greater sales potential for Yartemlea, is driving attention as traders celebrate the sharp move and see it as validation of the drugs commercial launch. The reaction is broadly bullish, though some traders criticize the analyst and speculate that other catalysts or short covering may also be contributing.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias settlement with Teva, which delays generic voclosporin entry and recognizes the validity of key patents, is driving discussion, with traders viewing it as a boost to the companys position in ongoing cases against other generic makers. Many are bullish on further settlements and a potential buyout, though those outcomes remain speculative and some investors are frustrated by the muted, low-volume trading.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Traders are linking UNIs rally to a perceived regulatory opening for permissioned AMM and tokenized-stock trading, as well as Robinhood-related adoption and fee-funded token burns. The reaction is largely bullish, though some traders warn that resistance and repeated rejections could stall the move; broader altcoin strength is also part of the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push

The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...

InflaRx N.V. (NASDAQ:IFRX) Short Interest Update

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...

InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday

InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...

InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...

InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reiterated a "buy" rating and set a $14.00 price target on shares of InflaRx in a report on Tuesday...

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy ratin...

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Should You Buy?

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Still a Buy...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases

Equity

Bearish Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Current Price	$2.08
Prev Close	$2.12
Open	$2.12
Dividend Yield	0.00%
50-Day Moving Average	$2.00
Beta	1.20
Avg. Volume	1.03M
PE Ratio	-2.02

52-Week High	$2.95
52-Week Low	$0.7984
Market Capitalization	$312.42M
EPS (Annual)	-$0.7654
Price to Book	1.87
Revenue Per Employee	$509.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

IFRX Fundamentals